Molecular/genomic profiling of endometrial carcinosarcoma
| Author, year | Number of patients | POLE mut | MSI-H/dMMR | p53 abnormal | NSMP | TMB |
| McConechy et al, 201520 | 30 | 1 (3.3%) | 1 (3.3%) | 23 (76.7%) | 5 (16.7%) | Not reported |
| Cherniack et al, 201721 | 57 | 1 (1.8%) | 2 (3.5%) | 50 (87.7%) | 4 (7%) | Not reported |
| Jones et al, 201722 | 361 | Not assessed | Not assessed | 68.8% | Not assessed | Not reported |
| Gotoh et al, 201923 | 92 | 10 (10.9%) | 24 (26.1%) | 49 (53.3%) | 9 (9.8%) | Not reported |
| Saijo et al, 201924 | 57 | Not assessed | 6 (10.5%) | 34 (59.6%) | Not assessable* | Not reported |
| Jones et al, 202125 | 27 | Not assessed | 12 (44.4%) | 11 (40.7%) | Not assessable* | Not reported |
| Kobayashi et al, 202126 | 4 | 0 | 1 (25%) | 2 (50%) | 1 (25%) | Not reported |
| Wilhite et al, 202227 | 26 black patients | Not assessed | 2 (7.7%) | 19 (73.1%) | Not assessable* | 2 (7.7%) |
| 23 white patients | Not assessed | 1 (4.5%) | 20 (86.4%) | Not assessable* | 1 (4.5%) |
*Not assessable since POLE was not tested.
MSI-H/dMMR, microsatellite instability high/mismatch repair deficient); NSMP, not specific mutational pattern; POLE, DNA polymerase epsilon, catalytic subunit gene; TMB, tumor mutational burden.